Peer Review | Early Circulating Tumor DNA Dynamics Predict Overall Survival in Solid Tumors: A Landscape Assessment | August 25, 2026 Share
Peer Review | Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs | July 28, 2026 Share
Peer Review | A Cross-National Review of Novel Oncology Approvals in the United States and China (2020–2025) | July 20, 2026 Share
Peer Review | Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project | July 16, 2026 Share
Peer Review | Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images | January 5, 2026 Share
Peer Review | Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery | December 2, 2025 Share
Peer Review | Hurry Up and Wait: Timelines and Takeaways from the Biomarker Qualification Program | October 28, 2025 Share
Peer Review | Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy | September 24, 2025 Share
Peer Review | Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies | June 16, 2025 Share
Peer Review | Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials | June 9, 2025 Share
